Michael Ruff, MD
Neurology · Rochester, MNNPI 1649611260
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $3,325 of the $3,756 with a category attached, or 88.5%. Servier Pharmaceuticals LLC accounts for 89.8% of it on its own, with 1 other manufacturer making up the rest. 2025 is the largest year on record at $3,372, more than ten times the $145 reported in 2019.
Across 6 payments — averaging $626.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Servier Pharmaceuticals LLC$3K
- Novocure Inc.$384
Across 18 payments — averaging $15,781 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novocure Inc.$202K
- Jazz Pharmaceuticals Inc.$82K
What the payments were for
- Consulting fees$3,32589%
- Food & beverage$43111%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Servier Pharmaceuticals LLC | 2 | $3,372 |
| Novocure Inc. | 4 | $384 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,756 in reported general payments places this provider in the 80th percentile of 434 neurology providers in Minnesota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 14 | $9,061 |
| Levetiracetam | 63 | $1,620 |
| Dexamethasone | 76 | $1,477 |
| Divalproex Sodium | 12 | $771 |
| Methylphenidate Hcl | 24 | $574 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 44 | $403 |
| Lacosamide | 11 | $315 |
| Propranolol Hcl ErPropranolol Hcl | 13 | $230 |
| Ondansetron Hcl | 32 | $212 |
| Prochlorperazine Maleate | 13 | $158 |
| Amlodipine Besylate | 14 | $108 |
| Donepezil Hcl | 19 | $107 |
| Olanzapine | 12 | $104 |
Paid to pharmacies, not to this prescriber.
Other neurology in Rochester
- Alejandro RabinsteinRochester$305K
- Sean PittockRochester$231K
- Wolfgang SingerRochester$128K
- Ronald PetersenRochester$126K
- Partha GhoshRochester$121K
- Eoin FlanaganRochester$55K
- Keith CoffmanRochester$24K
- Igal MirmanRochester$18K
- P James DyckRochester$17K
- Suresh KotagalRochester$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.